Researchers from the University of Rey Juan Carlos (Spain) and the University of Paris University (France) have developed a new photographer with silica and nanutartium ruthenium. This type of drugs are operated by light when they are inside the cancer cells and favor their abolition, less aggressive photodynamic therapy to the patient.
The use of metal drugs, metal compounds with chemotherapeutic properties in cancer treatments, is of great interest to patients with different types of tumors. It is estimated that around 60% of all cancer patients have been treated with metal compounds, mostly platinum, at least once during the development of the disease.
However, these metal compounds present a number of problems in their therapeutic use due to their high number of side effects and the potential for the tumor to resist. In addition, they present problems of solitude in biological media and dose restrictions that can be administered in some patients with problems in the immune system that are derived from the tumor's development.
The development of new drug nanoforms for use in different aggressive therapies, such as photodynamics, is one of the research lines in which the COMET-NANO group from the University of Rey Juan Carlos is working. "These drug-based therapies of the name are photosensitizers which, after exposure to a specific type of light with specific features, produce a special type of oxygen that can act against cancer cells that lead to death, "explained Santiago Gómez-Ruiz, COMET-NANO group researcher.
Therefore, the photosensitizers are used for photodynamic therapy. When the cancer cells absorb them and are exposed to light, the drug is activated and destroys cancer cells.
The study has gone to the formation of mesoporous silica nanoparticles that are less than 80 nanometers in size with ruthenium output. (Photo: URJC)
The latest work of the team in this area has been involved in the production of mesoporous silica nanopartics of a size that is less than 80 nanometers together with an outcome of ruthenium (Ru, low toxicity metal) with photodynamic activity under UV-A light. "We aim to study the possibilities of these and similar ruthenium-nanomaterial systems in the photodynamic treatment of different tumors," said Gómez-Ruiz.
This work is the result of collaborating with Professor Gilles Gasser (ERC Co-ordinator) Chimie ParisTech of the PSL Université Paris (France) and researchers from the University of Zurich (Switzerland). He was published in the Dalton Transactions magazine, as well as being published in the special volume on "Bioactive Reactivity of Coordination Compounds".
Today, only one form of ruthenium compound is being studied in clinical trials, the TLD-1433, prepared by the research group of Mc Farland (UNC Greensboro, United States). Researchers at URJC and PSL Université Paris have shown that the study of metallurgy ruthenium studied in the cells improves the results of cell death on cancer cells after applying light, opening the door to clinical studies of this type of therapeutic compounds in the future .
As Santiago Gómez-Ruiz develops: "In this sense, our work will focus on drugs that can be stimulated by less active and more unsafe light to the patient than UV-A, such as red or lower light -which, which would make them an excellent candidate for a direct application in certain telescopes of therapeutic interest at the moment ". (Source: SINC)